Providence Health & Services

This study tests whether adding a new drug (INBRX-106) to an existing immunotherapy (pembrolizumab) can shrink breast tumors before standard treatment. About 12 adults with stage II or III triple-negative breast cancer will receive the combo for two cycles. The goal is to see if …

This early-phase study tests a combination of a cancer vaccine (DPV-001) and two immune-boosting drugs (GITR agonist and anti-PD-1) in people with head and neck cancer that has returned or spread. The goal is to see if the treatment is safe and helps control the cancer. About 56 …

This study tests whether adding an experimental drug (GB1211) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with advanced melanoma or head and neck cancer. About 92 adults whose cancer has spread or cannot be removed will take pa…